Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose vaccine was authorized for emergency use in December for individuals age 18 and older, said its trial data shows that its vaccine is 96% effective in 12 to 17 year-olds who received at least one injection.  

Moderna yesterday announced that its vaccine booster, which remains in a phase 2 clinical trial, showed positive immune response for several COVID-19 variants, including those first discovered in South Africa and Brazil. The booster is intended for administration in patients who already completed the standard, two-dose regimen.

 

Related News Articles

Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…
Headline
The Food and Drug Administration today authorized Moderna’s COVID-19 vaccine for children aged 6 months through 17 years old and Pfizer’s COVID-19 vaccine for…
Headline
A Food and Drug Administration advisory committee today recommended the agency authorize Moderna’s COVID-19 two-dose vaccine for children aged 6 months…
Headline
An initial 10 million doses of COVID-19 vaccine are available for children under age 5 if the Food and Drug Administration authorizes and the Centers for…